These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 34161101)

  • 1. Dissecting Histone Deacetylase 3 in Multiple Disease Conditions: Selective Inhibition as a Promising Therapeutic Strategy.
    Adhikari N; Jha T; Ghosh B
    J Med Chem; 2021 Jul; 64(13):8827-8869. PubMed ID: 34161101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review.
    Sarkar R; Banerjee S; Amin SA; Adhikari N; Jha T
    Eur J Med Chem; 2020 Apr; 192():112171. PubMed ID: 32163814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic potential of selective histone deacetylase 3 inhibition.
    Zhang L; Chen Y; Jiang Q; Song W; Zhang L
    Eur J Med Chem; 2019 Jan; 162():534-542. PubMed ID: 30472601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors.
    Cao F; Zwinderman MRH; Dekker FJ
    Molecules; 2018 Mar; 23(3):. PubMed ID: 29498635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting histone deacetylases: Emerging applications beyond cancer.
    Raouf YS
    Drug Discov Today; 2024 Sep; 29(9):104094. PubMed ID: 38997001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HDAC3 is a potential validated target for cancer: An overview on the benzamide-based selective HDAC3 inhibitors through comparative SAR/QSAR/QAAR approaches.
    Adhikari N; Amin SA; Trivedi P; Jha T; Ghosh B
    Eur J Med Chem; 2018 Sep; 157():1127-1142. PubMed ID: 30179749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase 2: A potential therapeutic target for cancer and neurodegenerative disorders.
    Gediya P; Parikh PK; Vyas VK; Ghate MD
    Eur J Med Chem; 2021 Apr; 216():113332. PubMed ID: 33714914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase 3 inhibitors in learning and memory processes with special emphasis on benzamides.
    Amin SA; Adhikari N; Kotagiri S; Jha T; Ghosh B
    Eur J Med Chem; 2019 Mar; 166():369-380. PubMed ID: 30735902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of HDAC3 in inflammation: mechanisms and therapeutic implications.
    Watson N; Kuppuswamy S; Ledford WL; Sukumari-Ramesh S
    Front Immunol; 2024; 15():1419685. PubMed ID: 39050859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs.
    Wang Y; Wallach J; Duane S; Wang Y; Wu J; Wang J; Adejare A; Ma H
    Drug Des Devel Ther; 2017; 11():1369-1382. PubMed ID: 28496307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Class 1-Selective Histone Deacetylase (HDAC) Inhibitors Enhance HIV Latency Reversal while Preserving the Activity of HDAC Isoforms Necessary for Maximal HIV Gene Expression.
    Zaikos TD; Painter MM; Sebastian Kettinger NT; Terry VH; Collins KL
    J Virol; 2018 Mar; 92(6):. PubMed ID: 29298886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hsp90 regulates HDAC3-dependent gene transcription while HDAC3 regulates the functions of Hsp90.
    Kotwal A; Amere Subbarao S
    Cell Signal; 2020 Dec; 76():109801. PubMed ID: 33017618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase-3: Friend and foe of the brain.
    D'Mello SR
    Exp Biol Med (Maywood); 2020 Jul; 245(13):1130-1141. PubMed ID: 32486848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs.
    Xiao Y; Wang J; Zhao LY; Chen X; Zheng G; Zhang X; Liao D
    Chem Commun (Camb); 2020 Aug; 56(68):9866-9869. PubMed ID: 32840532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Focus on acetylation: the role of histone deacetylase inhibitors in cancer therapy and beyond.
    Konstantinopoulos PA; Karamouzis MV; Papavassiliou AG
    Expert Opin Investig Drugs; 2007 May; 16(5):569-71. PubMed ID: 17461732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Posttranslational modifications of histone deacetylases: implications for cardiovascular diseases.
    Eom GH; Kook H
    Pharmacol Ther; 2014 Aug; 143(2):168-80. PubMed ID: 24594235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HDAC3 inhibitors: a patent review of their broad-spectrum applications as therapeutic agents.
    Makgoba TB; Kapp E; Egieyeh S; Joubert J
    Expert Opin Ther Pat; 2024 Apr; 34(4):273-295. PubMed ID: 38873766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of histone deacetylase 3 in breast cancer.
    Rahbari R; Rasmi Y; Khadem-Ansari MH; Abdi M
    Med Oncol; 2022 May; 39(5):84. PubMed ID: 35578147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective inhibitors of zinc-dependent histone deacetylases. Therapeutic targets relevant to cancer.
    Kollar J; Frecer V
    Curr Pharm Des; 2015; 21(11):1472-502. PubMed ID: 25382430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective histone deacetylase small molecule inhibitors: recent progress and perspectives.
    Qin HT; Li HQ; Liu F
    Expert Opin Ther Pat; 2017 May; 27(5):621-636. PubMed ID: 28033734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.